Phapros (PEHA) Net Profit Rises 109% in 2025, Here's Why

Jakarta, CNBC Indonesia - The pharmaceutical issuer PT Phapros Tbk (PEHA) recorded a net profit of Rp27.44 billion for January to December 2025, up 109% compared to the same period in the previous year, which still reported a loss of Rp290.63 billion.

PEHA’s performance in 2025 was driven by double-digit sales growth and the success of its operational efficiency strategy. Phapros managed to book sales of Rp940.88 billion in 2025, a significant increase of 26.34% year-on-year (y-o-y). The sales increase occurred across all product segments. The over-the-counter (OTC) drug segment rose 43.20% y-o-y, the generic branded drug (OGB) segment grew 13.95% y-o-y, and the ethical segment soared by up to 54.94% y-o-y.

In addition, throughout 2025, the company was also able to reduce the cost of goods sold (COGS) by 5.41% to Rp448.37 billion compared to Rp474.03 billion in the previous year. This performance was further strengthened by operating expenses that were successfully reduced by 14.64% to Rp406.43 billion in 2025 compared to Rp476.12 billion in 2024.

Acting President Director of PT Phapros Tbk, Ida Rahmi Kurniasih, stated that strategic steps were taken through business and marketing transformation and product portfolio optimisation, which also became key factors in driving sales growth. The company also continued to implement production cost efficiencies through various innovations in multiple lines and improvements in distribution effectiveness, thus successfully reducing operating expenses significantly.

“This achievement is the result of five consistent performance improvement strategies implemented by the company. Fundamental business improvements have driven sales growth in all segments, thereby successfully restoring the company’s sustainable profitability. We are optimistic that the 2025 financial performance will serve as a strong foundation for strengthening financial performance and sustainable profitability going forward,” said Ida on Thursday (2/4/2026).

The cost restructuring strategy has also proven successful in achieving production efficiencies. This can be seen from the 5.41% decrease in COGS. The COGS to sales ratio in 2025 also fell significantly to 47.65% compared to 63.65% in 2024. The low COGS to sales ratio indicates that the production process is running very efficiently and yields a larger gross profit margin. PEHA also managed to cut marketing and distribution costs by 27.8% y-o-y.

Ida added that amid increasingly tight pharmaceutical industry competition, Phapros continues to take various strategic steps to enhance the company’s competitiveness, particularly with a commitment to fulfilling the latest CPOB and making consumer satisfaction the primary focus of its business.